Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…

Lynas confident of continuing operations in Malaysia

Rare earths producer Lynas Corp is confident of a future operating in Malaysia following the extension of its licence to operate by six months. The company said in an operational update that the extension, announced in August, provided an operational pathway for continued operation. However the company has yet to receive further approvals following concerns…

Canberra-esque madness kills the SME-focused innovation patent system

Comment by Peter Roberts Parliament has passed legislation killing the low cost innovation patent system, bowing to arguments from the Productivity Commission. Legislation killing the patent was passed by the Senate last week and followed an essentially economically-focused review that lacked transparency. This is yet another victory in a long list of destructive wins by…

Carbon Revolution signs contract with unnamed SUV company

Geelong-based one-piece carbon fibre wheel manufacturer Carbon Revolution has announced a contract with an unnamed global maker of sport utility vehicles (SUVs).   CEO Jake Dingle said the deal meant there were now five global automotive manufacturers using his company’s high-performance wheels.    “SUVs represent a very important new segment of the market for Carbon…

Admedus sells cardio business for $36 million

Cardiovascular device manufacturer Admedus (ASX: AHZ) has sold the distribution rights to its CardioCel and VascuCel product range for $A36.2 million to LeMaitre Vascular Inc. The company, whose ADAPT engineering process produces implantable tissue bio-scaffolds for a range of cardiovascular and vascular applications, will receive $22.8 million in an upfront payment. the remainder will flow…